Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CStone Pharmaceuticals Co. Ltd.

www.cstonepharma.com

Latest From CStone Pharmaceuticals Co. Ltd.

10 Commercial Trends To Watch In China in 2020

2019 will be remembered as a banner year for international drug makers as many grew at phenomenal rates in China, despite expansion of the “4+7” centralized procurement scheme and steep price cuts in exchange for reimbursement. As the government continues to emphasize affordability for cancer drugs and major anti-infectives, competition is heating up quickly and immune-oncology alone has seen six PD-1s elbowing each other for market share.

China Commercial

China Regulatory Roundup: AZ Gains PD-L1 Green Light Ahead Of Roche

Oncology continues to dominate new drug approvals in China as AstraZeneca gains the first clearance for a PD-L1 drug ahead of Roche. But there are as many as seven others in the class coming along, including from domestic firms Hengrui and CStone.

China Approvals

Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?

A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.

China Clinical Trials

After US Approval, BeiGene Set To Gain Sixth PD-1 Green Light In China

Beijing-based BeiGene is set to score two big wins in a row as it pursues innovation. After securing US approval for its BTK inhibitor zanubrutinib for mantle cell lymphoma, its PD-1 inhibitor has sailed through a technical review in China.

China Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • CStone Pharmaceuticals Co. Ltd.
  • Senior Management
  • Frank Jiang, MD, PhD, CEO
    Richard Yeh, CFO
    Jason Yang, MD, PhD, CMO
    Bing Yuan, PhD, CBO
    Jon Wang, PhD, CSO
  • Contact Info
  • CStone Pharmaceuticals Co. Ltd.
    Phone: 512 8718 6550
    218 Xinghu St. C1 Bldg, North Block
    Suzhou Ind. Pk
    Suzhou, 215123
    China
UsernamePublicRestriction

Register